智通财经APP获悉，荣昌生物(09995)高开近4%，截至发稿，涨3.94%，报85.8港元，成交额1364.22万港元。
消息面上，荣昌生物发布业绩，预计上半年实现营业收入约58.5亿元，同比增加约433%；预计实现归母净利润约为47亿元，与上年同期相比，实现扭亏为盈；预计归属于母公司所有者扣除非经常性损益后的净利润约43亿元。
公告显示，业绩增长主要由于公司核心产品泰它西普、维迪西妥单抗国内销售收入持续增长；公司与艾伯维就RC148签署独家授权许可协议，艾伯维将获得RC148 在大中华区以外地区的开发、生产和商业化的独家权利，公司技术授权收入大幅增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.